Articles
20.04.2023
EU HTA and what it means for manufacturers

Oncology products, advanced therapy medicinal products (ATMPs) and medical devices are entering the ...

Read more
Articles
13.04.2023
What are Joint Scientific Consultations and why th...

We explore joint scientific consultations; what they mean and why they are important to manufacturer...

Read more
Articles
03.04.2023
What is the joint clinical assessment and what doe...

We explore what the joint clinical assessment (JCA) is, its process and what future developments may...

Read more
Articles
07.03.2023
Are acute therapies and curative drugs more afford...

We've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...

Read more
Articles
22.02.2023
What are the risks and benefits of Early Access Pr...

Using Early Access Programs (EAPs) to give patients with life threatening conditions access to medic...

Read more
Articles
17.02.2023
How will governments face the cost of medical mira...

Among the most expensive therapies are gene therapies that show promise to transform inherited disor...

Read more
Articles
15.02.2023
What early access opportunities exist for innovati...

Our Market Access experts investigate what early access opportunities are available in China to enab...

Read more
Articles
08.02.2023
Which countries fund early access and why don’t ...

The provision of funding for Early Access Programmes is not ubiquitous. We explore which EU5 countri...

Read more
Articles
26.01.2023
What have we learned from the UK EAMS process?

Almost a decade after it's inception, what have we learned from the UK early access to medicines sch...

Read more
Articles
11.01.2023
What are the 5 Pricing & Market Access trends ...

Our experts provide an overview of the five key trends that could shape the pricing and market acces...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.